CD Private Equity Fund III (CD3.AX) Stock Competitors & Peer Comparison
See (CD3.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Asset Management Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CD3.AX | A$0.96 | +7.87% | 69.1M | -7.67 | -A$0.13 | +14.58% |
| A200.AX | A$146.96 | -0.26% | 9.8B | 21.01 | A$7.03 | +3.35% |
| AFI.AX | A$6.76 | +1.96% | 8.3B | 30.00 | A$0.22 | +5.05% |
| ARG.AX | A$9.01 | +1.01% | 6.8B | 25.65 | A$0.35 | +4.27% |
| GOLD.AX | A$52.90 | -2.07% | 5.5B | N/A | N/A | N/A |
| JHG.AX | A$39.49 | +0.33% | 4.9B | 12.86 | A$3.07 | +5.95% |
| GQG.AX | A$1.50 | +1.49% | 4.5B | 6.52 | A$0.23 | +14.13% |
| PNI.AX | A$16.82 | -0.74% | 4B | 30.29 | A$0.56 | +3.32% |
| AMP.AX | A$1.58 | -0.82% | 4B | 16.21 | A$0.10 | +2.49% |
| IFL.AX | A$4.79 | +0.00% | 3.2B | 28.18 | A$0.17 | N/A |
Stock Comparison
CD3.AX vs A200.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, A200.AX has a market cap of 9.8B. Regarding current trading prices, CD3.AX is priced at A$0.96, while A200.AX trades at A$146.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas A200.AX's P/E ratio is 21.01. In terms of profitability, CD3.AX's ROE is -0.07%, compared to A200.AX's ROE of N/A. Regarding short-term risk, CD3.AX is more volatile compared to A200.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check A200.AX's competition here
CD3.AX vs AFI.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, AFI.AX has a market cap of 8.3B. Regarding current trading prices, CD3.AX is priced at A$0.96, while AFI.AX trades at A$6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas AFI.AX's P/E ratio is 30.00. In terms of profitability, CD3.AX's ROE is -0.07%, compared to AFI.AX's ROE of +0.03%. Regarding short-term risk, CD3.AX is more volatile compared to AFI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check AFI.AX's competition here
CD3.AX vs ARG.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, ARG.AX has a market cap of 6.8B. Regarding current trading prices, CD3.AX is priced at A$0.96, while ARG.AX trades at A$9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas ARG.AX's P/E ratio is 25.65. In terms of profitability, CD3.AX's ROE is -0.07%, compared to ARG.AX's ROE of +0.04%. Regarding short-term risk, CD3.AX is more volatile compared to ARG.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check ARG.AX's competition here
CD3.AX vs GOLD.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, GOLD.AX has a market cap of 5.5B. Regarding current trading prices, CD3.AX is priced at A$0.96, while GOLD.AX trades at A$52.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas GOLD.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is -0.07%, compared to GOLD.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to GOLD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check GOLD.AX's competition here
CD3.AX vs JHG.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, JHG.AX has a market cap of 4.9B. Regarding current trading prices, CD3.AX is priced at A$0.96, while JHG.AX trades at A$39.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas JHG.AX's P/E ratio is 12.86. In terms of profitability, CD3.AX's ROE is -0.07%, compared to JHG.AX's ROE of +0.08%. Regarding short-term risk, CD3.AX is more volatile compared to JHG.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check JHG.AX's competition here
CD3.AX vs GQG.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, GQG.AX has a market cap of 4.5B. Regarding current trading prices, CD3.AX is priced at A$0.96, while GQG.AX trades at A$1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas GQG.AX's P/E ratio is 6.52. In terms of profitability, CD3.AX's ROE is -0.07%, compared to GQG.AX's ROE of +1.08%. Regarding short-term risk, CD3.AX is more volatile compared to GQG.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check GQG.AX's competition here
CD3.AX vs PNI.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, PNI.AX has a market cap of 4B. Regarding current trading prices, CD3.AX is priced at A$0.96, while PNI.AX trades at A$16.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas PNI.AX's P/E ratio is 30.29. In terms of profitability, CD3.AX's ROE is -0.07%, compared to PNI.AX's ROE of +0.14%. Regarding short-term risk, CD3.AX is more volatile compared to PNI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check PNI.AX's competition here
CD3.AX vs AMP.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, AMP.AX has a market cap of 4B. Regarding current trading prices, CD3.AX is priced at A$0.96, while AMP.AX trades at A$1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas AMP.AX's P/E ratio is 16.21. In terms of profitability, CD3.AX's ROE is -0.07%, compared to AMP.AX's ROE of +0.04%. Regarding short-term risk, CD3.AX is more volatile compared to AMP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check AMP.AX's competition here
CD3.AX vs IFL.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, IFL.AX has a market cap of 3.2B. Regarding current trading prices, CD3.AX is priced at A$0.96, while IFL.AX trades at A$4.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas IFL.AX's P/E ratio is 28.18. In terms of profitability, CD3.AX's ROE is -0.07%, compared to IFL.AX's ROE of +0.05%. Regarding short-term risk, CD3.AX is more volatile compared to IFL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check IFL.AX's competition here
CD3.AX vs VAP.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, VAP.AX has a market cap of 3B. Regarding current trading prices, CD3.AX is priced at A$0.96, while VAP.AX trades at A$96.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas VAP.AX's P/E ratio is 15.85. In terms of profitability, CD3.AX's ROE is -0.07%, compared to VAP.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to VAP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check VAP.AX's competition here
CD3.AX vs MFF.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, MFF.AX has a market cap of 3B. Regarding current trading prices, CD3.AX is priced at A$0.96, while MFF.AX trades at A$5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas MFF.AX's P/E ratio is 11.41. In terms of profitability, CD3.AX's ROE is -0.07%, compared to MFF.AX's ROE of +0.18%. Regarding short-term risk, CD3.AX is more volatile compared to MFF.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check MFF.AX's competition here
CD3.AX vs HBRD.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, HBRD.AX has a market cap of 2.5B. Regarding current trading prices, CD3.AX is priced at A$0.96, while HBRD.AX trades at A$10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas HBRD.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is -0.07%, compared to HBRD.AX's ROE of N/A. Regarding short-term risk, CD3.AX is more volatile compared to HBRD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check HBRD.AX's competition here
CD3.AX vs WLE.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, WLE.AX has a market cap of 1.8B. Regarding current trading prices, CD3.AX is priced at A$0.96, while WLE.AX trades at A$1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas WLE.AX's P/E ratio is 14.60. In terms of profitability, CD3.AX's ROE is -0.07%, compared to WLE.AX's ROE of +0.07%. Regarding short-term risk, CD3.AX is more volatile compared to WLE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check WLE.AX's competition here
CD3.AX vs PPT.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, PPT.AX has a market cap of 1.8B. Regarding current trading prices, CD3.AX is priced at A$0.96, while PPT.AX trades at A$15.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas PPT.AX's P/E ratio is 45.17. In terms of profitability, CD3.AX's ROE is -0.07%, compared to PPT.AX's ROE of -0.01%. Regarding short-term risk, CD3.AX is more volatile compared to PPT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check PPT.AX's competition here
CD3.AX vs MFG.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, MFG.AX has a market cap of 1.8B. Regarding current trading prices, CD3.AX is priced at A$0.96, while MFG.AX trades at A$9.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas MFG.AX's P/E ratio is 10.91. In terms of profitability, CD3.AX's ROE is -0.07%, compared to MFG.AX's ROE of +0.14%. Regarding short-term risk, CD3.AX is more volatile compared to MFG.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check MFG.AX's competition here
CD3.AX vs WAM.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, WAM.AX has a market cap of 1.7B. Regarding current trading prices, CD3.AX is priced at A$0.96, while WAM.AX trades at A$1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas WAM.AX's P/E ratio is 17.97. In terms of profitability, CD3.AX's ROE is -0.07%, compared to WAM.AX's ROE of +0.05%. Regarding short-term risk, CD3.AX is more volatile compared to WAM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check WAM.AX's competition here
CD3.AX vs CNI.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, CNI.AX has a market cap of 1.7B. Regarding current trading prices, CD3.AX is priced at A$0.96, while CNI.AX trades at A$2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas CNI.AX's P/E ratio is 14.29. In terms of profitability, CD3.AX's ROE is -0.07%, compared to CNI.AX's ROE of +0.08%. Regarding short-term risk, CD3.AX is more volatile compared to CNI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check CNI.AX's competition here
CD3.AX vs IAA.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, IAA.AX has a market cap of 1.6B. Regarding current trading prices, CD3.AX is priced at A$0.96, while IAA.AX trades at A$216.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas IAA.AX's P/E ratio is 21.08. In terms of profitability, CD3.AX's ROE is -0.07%, compared to IAA.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to IAA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check IAA.AX's competition here
CD3.AX vs PMGOLD.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, PMGOLD.AX has a market cap of 1.6B. Regarding current trading prices, CD3.AX is priced at A$0.96, while PMGOLD.AX trades at A$57.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas PMGOLD.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is -0.07%, compared to PMGOLD.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to PMGOLD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check PMGOLD.AX's competition here
CD3.AX vs ASIA.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, ASIA.AX has a market cap of 1.5B. Regarding current trading prices, CD3.AX is priced at A$0.96, while ASIA.AX trades at A$23.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas ASIA.AX's P/E ratio is 27.30. In terms of profitability, CD3.AX's ROE is -0.07%, compared to ASIA.AX's ROE of N/A. Regarding short-term risk, CD3.AX is more volatile compared to ASIA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check ASIA.AX's competition here
CD3.AX vs BKI.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, BKI.AX has a market cap of 1.4B. Regarding current trading prices, CD3.AX is priced at A$0.96, while BKI.AX trades at A$1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas BKI.AX's P/E ratio is 21.95. In terms of profitability, CD3.AX's ROE is -0.07%, compared to BKI.AX's ROE of +0.05%. Regarding short-term risk, CD3.AX is more volatile compared to BKI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check BKI.AX's competition here
CD3.AX vs GDG.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, GDG.AX has a market cap of 1.4B. Regarding current trading prices, CD3.AX is priced at A$0.96, while GDG.AX trades at A$3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas GDG.AX's P/E ratio is -35.47. In terms of profitability, CD3.AX's ROE is -0.07%, compared to GDG.AX's ROE of -0.05%. Regarding short-term risk, CD3.AX is more volatile compared to GDG.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check GDG.AX's competition here
CD3.AX vs AUI.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, AUI.AX has a market cap of 1.4B. Regarding current trading prices, CD3.AX is priced at A$0.96, while AUI.AX trades at A$11.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas AUI.AX's P/E ratio is 26.61. In terms of profitability, CD3.AX's ROE is -0.07%, compared to AUI.AX's ROE of +0.04%. Regarding short-term risk, CD3.AX is more volatile compared to AUI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check AUI.AX's competition here
CD3.AX vs ETPMAG.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, ETPMAG.AX has a market cap of 1.4B. Regarding current trading prices, CD3.AX is priced at A$0.96, while ETPMAG.AX trades at A$76.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas ETPMAG.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is -0.07%, compared to ETPMAG.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to ETPMAG.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check ETPMAG.AX's competition here
CD3.AX vs GDX.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, GDX.AX has a market cap of 1.3B. Regarding current trading prices, CD3.AX is priced at A$0.96, while GDX.AX trades at A$111.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas GDX.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is -0.07%, compared to GDX.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to GDX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check GDX.AX's competition here
CD3.AX vs QAU.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, QAU.AX has a market cap of 1.2B. Regarding current trading prices, CD3.AX is priced at A$0.96, while QAU.AX trades at A$31.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas QAU.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is -0.07%, compared to QAU.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to QAU.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check QAU.AX's competition here
CD3.AX vs MAF.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, MAF.AX has a market cap of 1.1B. Regarding current trading prices, CD3.AX is priced at A$0.96, while MAF.AX trades at A$5.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas MAF.AX's P/E ratio is 26.65. In terms of profitability, CD3.AX's ROE is -0.07%, compared to MAF.AX's ROE of +0.02%. Regarding short-term risk, CD3.AX is less volatile compared to MAF.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check MAF.AX's competition here
CD3.AX vs BBUS.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, BBUS.AX has a market cap of 1.1B. Regarding current trading prices, CD3.AX is priced at A$0.96, while BBUS.AX trades at A$24.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas BBUS.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is -0.07%, compared to BBUS.AX's ROE of N/A. Regarding short-term risk, CD3.AX is more volatile compared to BBUS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check BBUS.AX's competition here
CD3.AX vs DUI.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, DUI.AX has a market cap of 1.1B. Regarding current trading prices, CD3.AX is priced at A$0.96, while DUI.AX trades at A$5.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas DUI.AX's P/E ratio is 29.82. In terms of profitability, CD3.AX's ROE is -0.07%, compared to DUI.AX's ROE of +0.03%. Regarding short-term risk, CD3.AX is more volatile compared to DUI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check DUI.AX's competition here
CD3.AX vs RPL.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, RPL.AX has a market cap of 1.1B. Regarding current trading prices, CD3.AX is priced at A$0.96, while RPL.AX trades at A$2.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas RPL.AX's P/E ratio is 8.45. In terms of profitability, CD3.AX's ROE is -0.07%, compared to RPL.AX's ROE of +0.15%. Regarding short-term risk, CD3.AX is more volatile compared to RPL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check RPL.AX's competition here
CD3.AX vs MOAT.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, MOAT.AX has a market cap of 936.7M. Regarding current trading prices, CD3.AX is priced at A$0.96, while MOAT.AX trades at A$124.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas MOAT.AX's P/E ratio is 25.58. In terms of profitability, CD3.AX's ROE is -0.07%, compared to MOAT.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to MOAT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check MOAT.AX's competition here
CD3.AX vs CIN.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, CIN.AX has a market cap of 914.2M. Regarding current trading prices, CD3.AX is priced at A$0.96, while CIN.AX trades at A$34.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas CIN.AX's P/E ratio is 23.27. In terms of profitability, CD3.AX's ROE is -0.07%, compared to CIN.AX's ROE of +0.04%. Regarding short-term risk, CD3.AX is more volatile compared to CIN.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check CIN.AX's competition here
CD3.AX vs REIT.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, REIT.AX has a market cap of 835.9M. Regarding current trading prices, CD3.AX is priced at A$0.96, while REIT.AX trades at A$17.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas REIT.AX's P/E ratio is 22.62. In terms of profitability, CD3.AX's ROE is -0.07%, compared to REIT.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to REIT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check REIT.AX's competition here
CD3.AX vs MVA.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, MVA.AX has a market cap of 804.6M. Regarding current trading prices, CD3.AX is priced at A$0.96, while MVA.AX trades at A$24.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas MVA.AX's P/E ratio is 13.42. In terms of profitability, CD3.AX's ROE is -0.07%, compared to MVA.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to MVA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check MVA.AX's competition here
CD3.AX vs DJW.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, DJW.AX has a market cap of 718.2M. Regarding current trading prices, CD3.AX is priced at A$0.96, while DJW.AX trades at A$2.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas DJW.AX's P/E ratio is 19.50. In terms of profitability, CD3.AX's ROE is -0.07%, compared to DJW.AX's ROE of +0.04%. Regarding short-term risk, CD3.AX is more volatile compared to DJW.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check DJW.AX's competition here
CD3.AX vs HM1.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, HM1.AX has a market cap of 652.6M. Regarding current trading prices, CD3.AX is priced at A$0.96, while HM1.AX trades at A$2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas HM1.AX's P/E ratio is 33.71. In terms of profitability, CD3.AX's ROE is -0.07%, compared to HM1.AX's ROE of +0.02%. Regarding short-term risk, CD3.AX is more volatile compared to HM1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check HM1.AX's competition here
CD3.AX vs L1G.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, L1G.AX has a market cap of 650.1M. Regarding current trading prices, CD3.AX is priced at A$0.96, while L1G.AX trades at A$1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas L1G.AX's P/E ratio is 103.91. In terms of profitability, CD3.AX's ROE is -0.07%, compared to L1G.AX's ROE of +0.59%. Regarding short-term risk, CD3.AX is more volatile compared to L1G.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check L1G.AX's competition here
CD3.AX vs ACDC.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, ACDC.AX has a market cap of 635.9M. Regarding current trading prices, CD3.AX is priced at A$0.96, while ACDC.AX trades at A$161.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas ACDC.AX's P/E ratio is 21.81. In terms of profitability, CD3.AX's ROE is -0.07%, compared to ACDC.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to ACDC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check ACDC.AX's competition here
CD3.AX vs OPH.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, OPH.AX has a market cap of 620.9M. Regarding current trading prices, CD3.AX is priced at A$0.96, while OPH.AX trades at A$2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas OPH.AX's P/E ratio is 5.94. In terms of profitability, CD3.AX's ROE is -0.07%, compared to OPH.AX's ROE of N/A. Regarding short-term risk, CD3.AX is more volatile compared to OPH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check OPH.AX's competition here
CD3.AX vs YMAX.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, YMAX.AX has a market cap of 590.1M. Regarding current trading prices, CD3.AX is priced at A$0.96, while YMAX.AX trades at A$7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas YMAX.AX's P/E ratio is 21.29. In terms of profitability, CD3.AX's ROE is -0.07%, compared to YMAX.AX's ROE of N/A. Regarding short-term risk, CD3.AX is more volatile compared to YMAX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check YMAX.AX's competition here
CD3.AX vs GLS.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, GLS.AX has a market cap of 565.8M. Regarding current trading prices, CD3.AX is priced at A$0.96, while GLS.AX trades at A$1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas GLS.AX's P/E ratio is 60.54. In terms of profitability, CD3.AX's ROE is -0.07%, compared to GLS.AX's ROE of +0.02%. Regarding short-term risk, CD3.AX is more volatile compared to GLS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check GLS.AX's competition here
CD3.AX vs FGX.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, FGX.AX has a market cap of 556.8M. Regarding current trading prices, CD3.AX is priced at A$0.96, while FGX.AX trades at A$1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas FGX.AX's P/E ratio is 10.51. In terms of profitability, CD3.AX's ROE is -0.07%, compared to FGX.AX's ROE of +0.09%. Regarding short-term risk, CD3.AX is more volatile compared to FGX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check FGX.AX's competition here
CD3.AX vs MIR.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, MIR.AX has a market cap of 544M. Regarding current trading prices, CD3.AX is priced at A$0.96, while MIR.AX trades at A$2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas MIR.AX's P/E ratio is 59.97. In terms of profitability, CD3.AX's ROE is -0.07%, compared to MIR.AX's ROE of +0.01%. Regarding short-term risk, CD3.AX is more volatile compared to MIR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check MIR.AX's competition here
CD3.AX vs PMC.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, PMC.AX has a market cap of 523.5M. Regarding current trading prices, CD3.AX is priced at A$0.96, while PMC.AX trades at A$1.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas PMC.AX's P/E ratio is 58.83. In terms of profitability, CD3.AX's ROE is -0.07%, compared to PMC.AX's ROE of +0.02%. Regarding short-term risk, CD3.AX is more volatile compared to PMC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check PMC.AX's competition here
CD3.AX vs SLF.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, SLF.AX has a market cap of 512.8M. Regarding current trading prices, CD3.AX is priced at A$0.96, while SLF.AX trades at A$13.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas SLF.AX's P/E ratio is 15.70. In terms of profitability, CD3.AX's ROE is -0.07%, compared to SLF.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to SLF.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check SLF.AX's competition here
CD3.AX vs FSF.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, FSF.AX has a market cap of 490.9M. Regarding current trading prices, CD3.AX is priced at A$0.96, while FSF.AX trades at A$4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas FSF.AX's P/E ratio is 12.03. In terms of profitability, CD3.AX's ROE is -0.07%, compared to FSF.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to FSF.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check FSF.AX's competition here
CD3.AX vs AEF.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, AEF.AX has a market cap of 461M. Regarding current trading prices, CD3.AX is priced at A$0.96, while AEF.AX trades at A$4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas AEF.AX's P/E ratio is 18.56. In terms of profitability, CD3.AX's ROE is -0.07%, compared to AEF.AX's ROE of +0.55%. Regarding short-term risk, CD3.AX is more volatile compared to AEF.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check AEF.AX's competition here
CD3.AX vs PIC.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, PIC.AX has a market cap of 452.7M. Regarding current trading prices, CD3.AX is priced at A$0.96, while PIC.AX trades at A$1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas PIC.AX's P/E ratio is 15.93. In terms of profitability, CD3.AX's ROE is -0.07%, compared to PIC.AX's ROE of +0.06%. Regarding short-term risk, CD3.AX is more volatile compared to PIC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check PIC.AX's competition here
CD3.AX vs EQT.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, EQT.AX has a market cap of 428.7M. Regarding current trading prices, CD3.AX is priced at A$0.96, while EQT.AX trades at A$15.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas EQT.AX's P/E ratio is 11.59. In terms of profitability, CD3.AX's ROE is -0.07%, compared to EQT.AX's ROE of +0.10%. Regarding short-term risk, CD3.AX is more volatile compared to EQT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check EQT.AX's competition here
CD3.AX vs PE1.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, PE1.AX has a market cap of 414.8M. Regarding current trading prices, CD3.AX is priced at A$0.96, while PE1.AX trades at A$1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas PE1.AX's P/E ratio is 17.36. In terms of profitability, CD3.AX's ROE is -0.07%, compared to PE1.AX's ROE of +0.05%. Regarding short-term risk, CD3.AX is more volatile compared to PE1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check PE1.AX's competition here
CD3.AX vs GGUS.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, GGUS.AX has a market cap of 412.5M. Regarding current trading prices, CD3.AX is priced at A$0.96, while GGUS.AX trades at A$58.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas GGUS.AX's P/E ratio is 25.62. In terms of profitability, CD3.AX's ROE is -0.07%, compared to GGUS.AX's ROE of N/A. Regarding short-term risk, CD3.AX is more volatile compared to GGUS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check GGUS.AX's competition here
CD3.AX vs WMI.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, WMI.AX has a market cap of 400.9M. Regarding current trading prices, CD3.AX is priced at A$0.96, while WMI.AX trades at A$1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas WMI.AX's P/E ratio is 3.78. In terms of profitability, CD3.AX's ROE is -0.07%, compared to WMI.AX's ROE of +0.10%. Regarding short-term risk, CD3.AX is more volatile compared to WMI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check WMI.AX's competition here
CD3.AX vs RG8.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, RG8.AX has a market cap of 395.8M. Regarding current trading prices, CD3.AX is priced at A$0.96, while RG8.AX trades at A$2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas RG8.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is -0.07%, compared to RG8.AX's ROE of N/A. Regarding short-term risk, CD3.AX is more volatile compared to RG8.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check RG8.AX's competition here
CD3.AX vs PTM.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, PTM.AX has a market cap of 386.2M. Regarding current trading prices, CD3.AX is priced at A$0.96, while PTM.AX trades at A$0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas PTM.AX's P/E ratio is 69.50. In terms of profitability, CD3.AX's ROE is -0.07%, compared to PTM.AX's ROE of +0.03%. Regarding short-term risk, CD3.AX is less volatile compared to PTM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check PTM.AX's competition here
CD3.AX vs GLDN.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, GLDN.AX has a market cap of 379.7M. Regarding current trading prices, CD3.AX is priced at A$0.96, while GLDN.AX trades at A$45.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas GLDN.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is -0.07%, compared to GLDN.AX's ROE of N/A. Regarding short-term risk, CD3.AX is more volatile compared to GLDN.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check GLDN.AX's competition here
CD3.AX vs PAI.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, PAI.AX has a market cap of 359.1M. Regarding current trading prices, CD3.AX is priced at A$0.96, while PAI.AX trades at A$0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas PAI.AX's P/E ratio is 6.93. In terms of profitability, CD3.AX's ROE is -0.07%, compared to PAI.AX's ROE of +0.11%. Regarding short-term risk, CD3.AX is more volatile compared to PAI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check PAI.AX's competition here
CD3.AX vs PIA.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, PIA.AX has a market cap of 322.2M. Regarding current trading prices, CD3.AX is priced at A$0.96, while PIA.AX trades at A$1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas PIA.AX's P/E ratio is 31.25. In terms of profitability, CD3.AX's ROE is -0.07%, compared to PIA.AX's ROE of +0.03%. Regarding short-term risk, CD3.AX is more volatile compared to PIA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check PIA.AX's competition here
CD3.AX vs PAC.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, PAC.AX has a market cap of 317.9M. Regarding current trading prices, CD3.AX is priced at A$0.96, while PAC.AX trades at A$11.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas PAC.AX's P/E ratio is -14.04. In terms of profitability, CD3.AX's ROE is -0.07%, compared to PAC.AX's ROE of -0.13%. Regarding short-term risk, CD3.AX is more volatile compared to PAC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check PAC.AX's competition here
CD3.AX vs GXLD.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, GXLD.AX has a market cap of 283.6M. Regarding current trading prices, CD3.AX is priced at A$0.96, while GXLD.AX trades at A$57.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas GXLD.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is -0.07%, compared to GXLD.AX's ROE of N/A. Regarding short-term risk, CD3.AX is more volatile compared to GXLD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check GXLD.AX's competition here
CD3.AX vs SMLL.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, SMLL.AX has a market cap of 281.5M. Regarding current trading prices, CD3.AX is priced at A$0.96, while SMLL.AX trades at A$4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas SMLL.AX's P/E ratio is 20.41. In terms of profitability, CD3.AX's ROE is -0.07%, compared to SMLL.AX's ROE of N/A. Regarding short-term risk, CD3.AX is more volatile compared to SMLL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check SMLL.AX's competition here
CD3.AX vs MRE.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, MRE.AX has a market cap of 277.1M. Regarding current trading prices, CD3.AX is priced at A$0.96, while MRE.AX trades at A$1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas MRE.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is -0.07%, compared to MRE.AX's ROE of N/A. Regarding short-term risk, CD3.AX is more volatile compared to MRE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check MRE.AX's competition here
CD3.AX vs AMH.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, AMH.AX has a market cap of 276.8M. Regarding current trading prices, CD3.AX is priced at A$0.96, while AMH.AX trades at A$0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas AMH.AX's P/E ratio is 38.73. In terms of profitability, CD3.AX's ROE is -0.07%, compared to AMH.AX's ROE of +0.02%. Regarding short-term risk, CD3.AX is more volatile compared to AMH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check AMH.AX's competition here
CD3.AX vs FID.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, FID.AX has a market cap of 256M. Regarding current trading prices, CD3.AX is priced at A$0.96, while FID.AX trades at A$8.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas FID.AX's P/E ratio is 11.93. In terms of profitability, CD3.AX's ROE is -0.07%, compared to FID.AX's ROE of +0.32%. Regarding short-term risk, CD3.AX is more volatile compared to FID.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check FID.AX's competition here
CD3.AX vs OZR.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, OZR.AX has a market cap of 248.5M. Regarding current trading prices, CD3.AX is priced at A$0.96, while OZR.AX trades at A$16.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas OZR.AX's P/E ratio is 19.02. In terms of profitability, CD3.AX's ROE is -0.07%, compared to OZR.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to OZR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check OZR.AX's competition here
CD3.AX vs MNRS.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, MNRS.AX has a market cap of 240.5M. Regarding current trading prices, CD3.AX is priced at A$0.96, while MNRS.AX trades at A$13.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas MNRS.AX's P/E ratio is 13.73. In terms of profitability, CD3.AX's ROE is -0.07%, compared to MNRS.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to MNRS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check MNRS.AX's competition here
CD3.AX vs BBOZ.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, BBOZ.AX has a market cap of 229.6M. Regarding current trading prices, CD3.AX is priced at A$0.96, while BBOZ.AX trades at A$21.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas BBOZ.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is -0.07%, compared to BBOZ.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to BBOZ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check BBOZ.AX's competition here
CD3.AX vs CDM.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, CDM.AX has a market cap of 227.4M. Regarding current trading prices, CD3.AX is priced at A$0.96, while CDM.AX trades at A$0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas CDM.AX's P/E ratio is 4.29. In terms of profitability, CD3.AX's ROE is -0.07%, compared to CDM.AX's ROE of +0.18%. Regarding short-term risk, CD3.AX is more volatile compared to CDM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check CDM.AX's competition here
CD3.AX vs REP.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, REP.AX has a market cap of 218M. Regarding current trading prices, CD3.AX is priced at A$0.96, while REP.AX trades at A$0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas REP.AX's P/E ratio is 22.60. In terms of profitability, CD3.AX's ROE is -0.07%, compared to REP.AX's ROE of +0.02%. Regarding short-term risk, CD3.AX is more volatile compared to REP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check REP.AX's competition here
CD3.AX vs WAX.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, WAX.AX has a market cap of 215.3M. Regarding current trading prices, CD3.AX is priced at A$0.96, while WAX.AX trades at A$1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas WAX.AX's P/E ratio is -198.64. In terms of profitability, CD3.AX's ROE is -0.07%, compared to WAX.AX's ROE of -0.00%. Regarding short-term risk, CD3.AX is more volatile compared to WAX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check WAX.AX's competition here
CD3.AX vs QVE.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, QVE.AX has a market cap of 212.6M. Regarding current trading prices, CD3.AX is priced at A$0.96, while QVE.AX trades at A$0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas QVE.AX's P/E ratio is 23.38. In terms of profitability, CD3.AX's ROE is -0.07%, compared to QVE.AX's ROE of +0.04%. Regarding short-term risk, CD3.AX is more volatile compared to QVE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check QVE.AX's competition here
CD3.AX vs URNM.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, URNM.AX has a market cap of 210.7M. Regarding current trading prices, CD3.AX is priced at A$0.96, while URNM.AX trades at A$10.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas URNM.AX's P/E ratio is 12.11. In terms of profitability, CD3.AX's ROE is -0.07%, compared to URNM.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to URNM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check URNM.AX's competition here
CD3.AX vs MVS.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, MVS.AX has a market cap of 206.9M. Regarding current trading prices, CD3.AX is priced at A$0.96, while MVS.AX trades at A$20.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas MVS.AX's P/E ratio is 17.19. In terms of profitability, CD3.AX's ROE is -0.07%, compared to MVS.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to MVS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check MVS.AX's competition here
CD3.AX vs CVC.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, CVC.AX has a market cap of 198.3M. Regarding current trading prices, CD3.AX is priced at A$0.96, while CVC.AX trades at A$1.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas CVC.AX's P/E ratio is -43.21. In terms of profitability, CD3.AX's ROE is -0.07%, compared to CVC.AX's ROE of -0.03%. Regarding short-term risk, CD3.AX is more volatile compared to CVC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check CVC.AX's competition here
CD3.AX vs EZL.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, EZL.AX has a market cap of 196.8M. Regarding current trading prices, CD3.AX is priced at A$0.96, while EZL.AX trades at A$1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas EZL.AX's P/E ratio is 11.16. In terms of profitability, CD3.AX's ROE is -0.07%, compared to EZL.AX's ROE of +0.16%. Regarding short-term risk, CD3.AX is more volatile compared to EZL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check EZL.AX's competition here
CD3.AX vs WAR.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, WAR.AX has a market cap of 194.5M. Regarding current trading prices, CD3.AX is priced at A$0.96, while WAR.AX trades at A$1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas WAR.AX's P/E ratio is 10.95. In terms of profitability, CD3.AX's ROE is -0.07%, compared to WAR.AX's ROE of +0.08%. Regarding short-term risk, CD3.AX is more volatile compared to WAR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check WAR.AX's competition here
CD3.AX vs WMA.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, WMA.AX has a market cap of 193.5M. Regarding current trading prices, CD3.AX is priced at A$0.96, while WMA.AX trades at A$0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas WMA.AX's P/E ratio is 23.84. In terms of profitability, CD3.AX's ROE is -0.07%, compared to WMA.AX's ROE of +0.04%. Regarding short-term risk, CD3.AX is more volatile compared to WMA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check WMA.AX's competition here
CD3.AX vs FOR.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, FOR.AX has a market cap of 151.3M. Regarding current trading prices, CD3.AX is priced at A$0.96, while FOR.AX trades at A$1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas FOR.AX's P/E ratio is 10.10. In terms of profitability, CD3.AX's ROE is -0.07%, compared to FOR.AX's ROE of +0.16%. Regarding short-term risk, CD3.AX is more volatile compared to FOR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check FOR.AX's competition here
CD3.AX vs RYD.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, RYD.AX has a market cap of 142.2M. Regarding current trading prices, CD3.AX is priced at A$0.96, while RYD.AX trades at A$1.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas RYD.AX's P/E ratio is -145.87. In terms of profitability, CD3.AX's ROE is -0.07%, compared to RYD.AX's ROE of -0.01%. Regarding short-term risk, CD3.AX is more volatile compared to RYD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check RYD.AX's competition here
CD3.AX vs SEC.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, SEC.AX has a market cap of 140.3M. Regarding current trading prices, CD3.AX is priced at A$0.96, while SEC.AX trades at A$2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas SEC.AX's P/E ratio is 9.11. In terms of profitability, CD3.AX's ROE is -0.07%, compared to SEC.AX's ROE of +0.11%. Regarding short-term risk, CD3.AX is more volatile compared to SEC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check SEC.AX's competition here
CD3.AX vs GOW.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, GOW.AX has a market cap of 120.3M. Regarding current trading prices, CD3.AX is priced at A$0.96, while GOW.AX trades at A$2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas GOW.AX's P/E ratio is -59.90. In terms of profitability, CD3.AX's ROE is -0.07%, compared to GOW.AX's ROE of -0.01%. Regarding short-term risk, CD3.AX is more volatile compared to GOW.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check GOW.AX's competition here
CD3.AX vs SNC.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, SNC.AX has a market cap of 115.2M. Regarding current trading prices, CD3.AX is priced at A$0.96, while SNC.AX trades at A$0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas SNC.AX's P/E ratio is 13.54. In terms of profitability, CD3.AX's ROE is -0.07%, compared to SNC.AX's ROE of +0.12%. Regarding short-term risk, CD3.AX is more volatile compared to SNC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check SNC.AX's competition here
CD3.AX vs EAI.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, EAI.AX has a market cap of 114.4M. Regarding current trading prices, CD3.AX is priced at A$0.96, while EAI.AX trades at A$0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas EAI.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is -0.07%, compared to EAI.AX's ROE of N/A. Regarding short-term risk, CD3.AX is more volatile compared to EAI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check EAI.AX's competition here
CD3.AX vs ENN.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, ENN.AX has a market cap of 108.2M. Regarding current trading prices, CD3.AX is priced at A$0.96, while ENN.AX trades at A$0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas ENN.AX's P/E ratio is -5.86. In terms of profitability, CD3.AX's ROE is -0.07%, compared to ENN.AX's ROE of -0.11%. Regarding short-term risk, CD3.AX is more volatile compared to ENN.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check ENN.AX's competition here
CD3.AX vs UBA.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, UBA.AX has a market cap of 107.4M. Regarding current trading prices, CD3.AX is priced at A$0.96, while UBA.AX trades at A$18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas UBA.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is -0.07%, compared to UBA.AX's ROE of N/A. Regarding short-term risk, CD3.AX is more volatile compared to UBA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check UBA.AX's competition here
CD3.AX vs AUMF.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, AUMF.AX has a market cap of 105.1M. Regarding current trading prices, CD3.AX is priced at A$0.96, while AUMF.AX trades at A$38.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas AUMF.AX's P/E ratio is 18.55. In terms of profitability, CD3.AX's ROE is -0.07%, compared to AUMF.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to AUMF.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check AUMF.AX's competition here
CD3.AX vs LRT.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, LRT.AX has a market cap of 103.9M. Regarding current trading prices, CD3.AX is priced at A$0.96, while LRT.AX trades at A$2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas LRT.AX's P/E ratio is 0.94. In terms of profitability, CD3.AX's ROE is -0.07%, compared to LRT.AX's ROE of +0.92%. Regarding short-term risk, CD3.AX is more volatile compared to LRT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check LRT.AX's competition here
CD3.AX vs EP1.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, EP1.AX has a market cap of 98.7M. Regarding current trading prices, CD3.AX is priced at A$0.96, while EP1.AX trades at A$0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas EP1.AX's P/E ratio is -4.29. In terms of profitability, CD3.AX's ROE is -0.07%, compared to EP1.AX's ROE of -0.22%. Regarding short-term risk, CD3.AX is less volatile compared to EP1.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check EP1.AX's competition here
CD3.AX vs CAM.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, CAM.AX has a market cap of 97.5M. Regarding current trading prices, CD3.AX is priced at A$0.96, while CAM.AX trades at A$0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas CAM.AX's P/E ratio is 11.52. In terms of profitability, CD3.AX's ROE is -0.07%, compared to CAM.AX's ROE of +0.07%. Regarding short-term risk, CD3.AX is more volatile compared to CAM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check CAM.AX's competition here
CD3.AX vs SBZ.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, SBZ.AX has a market cap of 91.8M. Regarding current trading prices, CD3.AX is priced at A$0.96, while SBZ.AX trades at A$0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas SBZ.AX's P/E ratio is -5.67. In terms of profitability, CD3.AX's ROE is -0.07%, compared to SBZ.AX's ROE of -0.03%. Regarding short-term risk, CD3.AX is more volatile compared to SBZ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check SBZ.AX's competition here
CD3.AX vs TOP.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, TOP.AX has a market cap of 91.8M. Regarding current trading prices, CD3.AX is priced at A$0.96, while TOP.AX trades at A$0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas TOP.AX's P/E ratio is 5.98. In terms of profitability, CD3.AX's ROE is -0.07%, compared to TOP.AX's ROE of +0.10%. Regarding short-term risk, CD3.AX is more volatile compared to TOP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check TOP.AX's competition here
CD3.AX vs ACQ.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, ACQ.AX has a market cap of 80.7M. Regarding current trading prices, CD3.AX is priced at A$0.96, while ACQ.AX trades at A$0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas ACQ.AX's P/E ratio is 4.36. In terms of profitability, CD3.AX's ROE is -0.07%, compared to ACQ.AX's ROE of +0.17%. Regarding short-term risk, CD3.AX is more volatile compared to ACQ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check ACQ.AX's competition here
CD3.AX vs WAA.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, WAA.AX has a market cap of 77.5M. Regarding current trading prices, CD3.AX is priced at A$0.96, while WAA.AX trades at A$1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas WAA.AX's P/E ratio is 5.94. In terms of profitability, CD3.AX's ROE is -0.07%, compared to WAA.AX's ROE of +0.17%. Regarding short-term risk, CD3.AX is more volatile compared to WAA.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check WAA.AX's competition here
CD3.AX vs CAF.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, CAF.AX has a market cap of 77.5M. Regarding current trading prices, CD3.AX is priced at A$0.96, while CAF.AX trades at A$0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas CAF.AX's P/E ratio is 18.50. In terms of profitability, CD3.AX's ROE is -0.07%, compared to CAF.AX's ROE of +0.13%. Regarding short-term risk, CD3.AX is more volatile compared to CAF.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check CAF.AX's competition here
CD3.AX vs INES.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, INES.AX has a market cap of 72M. Regarding current trading prices, CD3.AX is priced at A$0.96, while INES.AX trades at A$3.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas INES.AX's P/E ratio is 21.63. In terms of profitability, CD3.AX's ROE is -0.07%, compared to INES.AX's ROE of +0.00%. Regarding short-term risk, CD3.AX is more volatile compared to INES.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check INES.AX's competition here
CD3.AX vs SB2.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, SB2.AX has a market cap of 68.8M. Regarding current trading prices, CD3.AX is priced at A$0.96, while SB2.AX trades at A$0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas SB2.AX's P/E ratio is 16.88. In terms of profitability, CD3.AX's ROE is -0.07%, compared to SB2.AX's ROE of +0.03%. Regarding short-term risk, CD3.AX is more volatile compared to SB2.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check SB2.AX's competition here
CD3.AX vs PCG.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, PCG.AX has a market cap of 67.1M. Regarding current trading prices, CD3.AX is priced at A$0.96, while PCG.AX trades at A$0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas PCG.AX's P/E ratio is 12.57. In terms of profitability, CD3.AX's ROE is -0.07%, compared to PCG.AX's ROE of +0.01%. Regarding short-term risk, CD3.AX is more volatile compared to PCG.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check PCG.AX's competition here
CD3.AX vs PFG.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, PFG.AX has a market cap of 60.1M. Regarding current trading prices, CD3.AX is priced at A$0.96, while PFG.AX trades at A$0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas PFG.AX's P/E ratio is 11.54. In terms of profitability, CD3.AX's ROE is -0.07%, compared to PFG.AX's ROE of +0.08%. Regarding short-term risk, CD3.AX is less volatile compared to PFG.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check PFG.AX's competition here
CD3.AX vs TGP.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, TGP.AX has a market cap of 59.1M. Regarding current trading prices, CD3.AX is priced at A$0.96, while TGP.AX trades at A$0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas TGP.AX's P/E ratio is 15.00. In terms of profitability, CD3.AX's ROE is -0.07%, compared to TGP.AX's ROE of +0.02%. Regarding short-term risk, CD3.AX is less volatile compared to TGP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for CD3.AX.Check TGP.AX's competition here
CD3.AX vs USD.AX Comparison June 2026
CD3.AX plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD3.AX stands at 69.1M. In comparison, USD.AX has a market cap of 55.6M. Regarding current trading prices, CD3.AX is priced at A$0.96, while USD.AX trades at A$14.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD3.AX currently has a P/E ratio of -7.67, whereas USD.AX's P/E ratio is N/A. In terms of profitability, CD3.AX's ROE is -0.07%, compared to USD.AX's ROE of N/A. Regarding short-term risk, CD3.AX is more volatile compared to USD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for CD3.AX.Check USD.AX's competition here